Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study | Journal of Translational Medicine User montaukwhaler, in the non small cell lung cancer subreddit, 26 Feb 2019